ARCANGELI, STEFANO
 Distribuzione geografica
Continente #
AS - Asia 11.066
NA - Nord America 9.380
EU - Europa 4.640
SA - Sud America 1.378
AF - Africa 214
OC - Oceania 11
Continente sconosciuto - Info sul continente non disponibili 3
Totale 26.692
Nazione #
US - Stati Uniti d'America 9.174
SG - Singapore 5.815
VN - Vietnam 1.524
HK - Hong Kong 1.400
CN - Cina 1.273
IT - Italia 1.126
BR - Brasile 1.032
RU - Federazione Russa 864
DE - Germania 637
IE - Irlanda 623
SE - Svezia 369
FR - Francia 253
IN - India 204
GB - Regno Unito 198
UA - Ucraina 157
AR - Argentina 140
BD - Bangladesh 139
KR - Corea 106
ID - Indonesia 94
CA - Canada 92
FI - Finlandia 91
IQ - Iraq 77
MX - Messico 71
TR - Turchia 69
NL - Olanda 67
PK - Pakistan 61
ZA - Sudafrica 60
EC - Ecuador 51
AT - Austria 46
CO - Colombia 46
SA - Arabia Saudita 44
ES - Italia 43
PH - Filippine 42
PL - Polonia 40
MA - Marocco 35
JP - Giappone 30
UZ - Uzbekistan 30
VE - Venezuela 28
EG - Egitto 26
CH - Svizzera 25
CL - Cile 25
PY - Paraguay 20
TH - Thailandia 20
TN - Tunisia 20
JO - Giordania 18
MY - Malesia 17
AE - Emirati Arabi Uniti 14
KE - Kenya 14
UY - Uruguay 14
CZ - Repubblica Ceca 13
ET - Etiopia 13
JM - Giamaica 13
DK - Danimarca 12
LT - Lituania 12
BO - Bolivia 11
KZ - Kazakistan 11
PE - Perù 11
AL - Albania 10
AU - Australia 9
NP - Nepal 9
OM - Oman 9
DZ - Algeria 8
PS - Palestinian Territory 8
PT - Portogallo 8
GR - Grecia 7
HN - Honduras 6
IL - Israele 6
PA - Panama 6
RO - Romania 6
SN - Senegal 6
AZ - Azerbaigian 5
KG - Kirghizistan 5
LB - Libano 5
LY - Libia 5
RS - Serbia 5
SY - Repubblica araba siriana 5
BG - Bulgaria 4
DO - Repubblica Dominicana 4
IR - Iran 4
SC - Seychelles 4
SI - Slovenia 4
AM - Armenia 3
AO - Angola 3
BE - Belgio 3
BH - Bahrain 3
BW - Botswana 3
CR - Costa Rica 3
EE - Estonia 3
EU - Europa 3
HR - Croazia 3
NG - Nigeria 3
TT - Trinidad e Tobago 3
ZM - Zambia 3
BT - Bhutan 2
BY - Bielorussia 2
CG - Congo 2
CI - Costa d'Avorio 2
GE - Georgia 2
GT - Guatemala 2
KW - Kuwait 2
Totale 26.658
Città #
Hong Kong 1.385
Singapore 1.283
Fairfield 1.048
Ashburn 927
Ann Arbor 823
Dublin 616
San Jose 557
Ho Chi Minh City 469
Frankfurt am Main 462
Woodbridge 429
Seattle 415
Wilmington 406
Santa Clara 377
Hanoi 351
Houston 347
Cambridge 341
New York 250
Chicago 241
Milan 239
Princeton 237
The Dalles 233
Hefei 218
Los Angeles 198
Beijing 149
Lauterbourg 135
Moscow 135
Chandler 123
Altamura 110
Lawrence 108
Dallas 105
Seoul 102
São Paulo 99
Dearborn 89
Jacksonville 89
Buffalo 80
Munich 76
Rome 76
San Diego 69
Da Nang 68
Nanjing 67
Council Bluffs 61
Helsinki 54
Haiphong 44
Rio de Janeiro 43
Guangzhou 42
Jakarta 42
Andover 41
London 41
Shanghai 41
Salt Lake City 37
Toronto 36
Warsaw 34
Biên Hòa 32
Nuremberg 32
Orem 28
Tashkent 27
Dong Ket 26
Ha Long 26
Johannesburg 26
Ninh Bình 26
Ottawa 26
Tokyo 26
Shenyang 25
Hebei 24
Belo Horizonte 23
Lahore 23
Nanchang 23
Vienna 22
Baghdad 21
Changsha 21
Can Tho 20
Curitiba 20
Brooklyn 19
Chennai 19
Dhaka 19
Lappeenranta 19
Bắc Ninh 18
Hải Dương 18
Mexico City 18
Thái Nguyên 18
Campinas 17
Guayaquil 17
Jiaxing 17
Stockholm 17
Tampa 17
Turku 17
Xi'an 17
Zurich 17
Denver 16
Jeddah 16
Phoenix 16
Quận Một 16
Vũng Tàu 16
Amman 15
Elk Grove Village 15
Medellín 15
Pune 15
San Francisco 15
Buenos Aires 14
Cape Town 14
Totale 15.012
Nome #
Effetti immunologici della radioterapia 551
The ‘Liaisons dangereuses’ Between Lung Cancer and Interstitial Lung Diseases: A Focus on Acute Exacerbation 487
Combination of novel systemic agents and radiotherapy for solid tumors – part I: An AIRO (Italian association of radiotherapy and clinical oncology) overview focused on treatment efficacy 446
Leukotoxicity after moderately Hypofractionated radiotherapy versus conventionally fractionated dose escalated radiotherapy for localized prostate Cancer: A secondary analysis from a randomized study 405
Validation of an easy questionnaire on the assessment of salt habit: the MINISAL-SIIA Study Program 365
Single-Isocenter Linac-Based Radiosurgery for Brain Metastases with Coplanar Arcs: A Dosimetric and Clinical Analysis 332
Treatment outcomes and patterns of radiologic appearance after hypofractionated image-guided radiotherapy delivered with helical tomotherapy (HHT) for lung tumours 331
International validation of the EORTC QLQ-PRT20 module for assessment of quality of life symptoms relating to radiation proctitis: a phase IV study 326
Extreme hypofractionation for early prostate cancer: Biology meets technology 320
Combination of novel systemic agents and radiotherapy for solid tumors – Part II: An AIRO (Italian association of radiotherapy and clinical oncology) overview focused on treatment toxicity 316
Consolidative ablative radiotherapy improves outcomes in oligometastatic non-small cell lung cancer: A further step toward new evidence 312
"Hit the primary": A paradigm shift in the treatment of metastatic prostate cancer? 312
Radiation therapy does not increase survival in addition to standard androgen deprivation therapy for metastatic prostate cancer: An old, faded picture? 310
Moderate hypofractionation for prostate cancer 307
A Systematic Review of Radical Cystectomy Versus Organ Preserving Trimodal Therapy in Muscle-Invasive Bladder Cancer 305
Re-irradiation for esophageal cancer 304
Consensus statements on ablative radiotherapy for oligometastatic prostate cancer: A position paper of Italian Association of Radiotherapy and Clinical Oncology (AIRO) 303
Moderately escalated hypofractionated (chemo) radiotherapy delivered with helical intensity-modulated technique in stage III unresectable non-small cell lung cancer 300
Combination of androgen deprivation therapy and radiotherapy for localized prostate cancer in the contemporary era 300
Macroscopic Hematuria After Conventional or Hypofractionated Radiation Therapy: Results From a Prospective Phase 3 Study 299
Will SBRT replace conventional radiotherapy in patients with low-intermediate risk prostate cancer? A review 293
Is two-dimensional field definition sufficient for pelvic node coverage in rectal cancer compared to technical three-dimensional definition? 273
Stereotactic Body Radiation Therapy With Ablative Dose on Liver Metastases: Radiation-induced Liver Disease (RILD) and Toxicity Assessment 265
Dose-escalated Radiotherapy for Stage III Unresectable Non-small Cell Lung Cancer: Have We Come to a Standstill? 264
Guidelines on prostate carcinoma - AIRO, 2016 263
Association between treatment-related lymphopenia and survival in glioblastoma patients following postoperative chemoradiotherapy 261
Post-operative management of brain metastases: GRADE-based clinical practice recommendations on behalf of the Italian Association of Radiotherapy and Clinical Oncology (AIRO) 257
Optimal scheduling of hypofractionated radiotherapy for localized prostate cancer: A systematic review and metanalysis of randomized clinical trials 256
« Augmented radiotherapy » in the management of high-risk prostate cancer (PCa): A systematic review 250
Oligometastasis and local ablation in the era of systemic targeted and immunotherapy 244
Letter to the Editor regarding ESTRO-ASTRO guidelines on lung cancer radiotherapy during COVID-19 pandemic 236
COVID-19 Outbreak and Cancer Radiotherapy Disruption in Lombardy, Northern Italy 219
Moderate hypofractionated helical tomotherapy for localized prostate cancer: preliminary report of an observational prospective study 218
Urethra-sparing prostate cancer radiotherapy: Current practices and future insights from an international survey 211
Stereotactic Body Radiation Therapy for Prostate Cancer is Getting Mature: 10-Year Outcomes From 3 Prospective Trials 208
In vivo dosimetry of total body irradiation patients: A 10 year retrospective analysis 207
Treatment outcome and compliance to dose-intensified linac-based SBRT for unfavorable prostate tumors using a novel real-time organ-motion tracking 205
Can volumetric modulated arc therapy with flattening filter free beams play a role in stereotactic body radiotherapy for liver lesions? A volume-based analysis 204
Almost one year of COVID-19 pandemic: how radiotherapy centers have counteracted its impact on cancer treatment in Lombardy, Italy. CODRAL/AIRO-L study 201
Attitudes, practices and perspectives on imaging strategies in prostate cancer: a national cross-sectional survey involving expert radiation oncologists on behalf of AIRO (Italian association of radiotherapy and clinical oncology) GU group 198
Policies for reirradiation of recurrent high-grade gliomas: a survey among Italian radiation oncologists 195
High-dose-rate brachytherapy as monotherapy for localized prostate cancer using three different doses - 14 years of single-centre experience 192
Synchronized Contrast-Enhanced 4DCT Simulation for Target Volume Delineation in Abdominal SBRT 191
Management of patients with extensive small-cell lung cancer in the immunotherapy era: an Italian consensus through a Delphi approach 190
Updated results and patterns of failure in a randomized hypofractionation trial for high-risk prostate cancer 189
Radical cystectomy versus organ-sparing trimodality treatment in muscle-invasive bladder cancer: A systematic review of clinical trials 187
Moderate hypofractionation in high-risk, organ-confined prostate cancer: Final results of a phase III randomized trial 186
Toxicity and cosmesis outcomes after single fraction partial breast irradiation in early stage breast cancer 186
Lexicographic optimization-based planning for stereotactic radiosurgery of brain metastases 185
Long-term outcomes of volume de-escalation for breast nodal irradiation 185
Radical radiation therapy for oligometastatic breast cancer: Results of a prospective phase II trial 185
Safety culture to improve accidental event reporting in radiotherapy 185
10-yr Results of Moderately Hypofractionated Postoperative Radiotherapy for Prostate Cancer Focused on Treatment Related Toxicity 183
Dosimetric and Clinical Prognostic Factors in Single-Isocenter Linac-Based Stereotactic Radiotherapy for Brain Metastases 181
Short-term pain control after palliative radiotherapy for uncomplicated bone metastases: a prospective cohort study 180
Toxicity profile and Patient-Reported outcomes following salvage Stereotactic Ablative Radiation Therapy to the prostate Bed: The POPART multicentric prospective study 178
GUROPA survey: genito-urinary radiation oncology prescription attitudes 178
A critical review on oligometastatic disease: a radiation oncologist’s perspective 176
Acute Toxicity and Quality of Life in a Post-Prostatectomy Ablative Radiation Therapy (POPART) Multicentric Trial 174
Postoperative Hypofractionated Radiotherapy for Prostate Cancer 173
Stereotactic body radiation therapy for liver tumours using flattening filter free beam: dosimetric and technical considerations 173
Ablative Radiation Therapy for Unfavorable Prostate Tumors (ABRUPT): Preliminary Analysis of Toxicity and Quality of Life from a Prospective Study 172
Treatment Optimization in Linac-Based SBRT for Localized Prostate Cancer: A Single-Arc versus Dual-Arc Plan Comparison 172
Phase I-II study of intraoperative radiation therapy (IORT) after radical prostatectomy for prostate cancer 171
Dosimetric Impact of Intrafraction Prostate Motion and Interfraction Anatomical Changes in Dose-Escalated Linac-Based SBRT 170
Automated segmentation in pelvic radiotherapy: A comprehensive evaluation of ATLAS-, machine learning-, and deep learning-based models 170
A predictive model of polymetastatic disease from a multicenter large retrospectIve database on colorectal lung metastases treated with stereotactic ablative radiotherapy: The RED LaIT-SABR study 170
Hypofractionated radiotherapy for organ-confined prostate cancer: Is less more? 167
DVHs evaluation in brain metastases stereotactic radiotherapy treatment plans 167
Analysis of toxicity in patients with high risk prostate cancer treated with intensity-modulated pelvic radiation therapy and simultaneous integrated dose escalation to prostate area 166
A systematic review and meta-analysis of clinical trials of bladder-sparing trimodality treatment for muscle-invasive bladder cancer (MIBC) 166
Analysis of patients with locally advanced rectal cancer given neoadjuvant radiochemotherapy with or without RT dose intensification: A multicenter retrospective study – ATLANTIS part I 165
Time to Next Treatment Following Sub-Ablative Progression Directed Radiation Therapy for Oligoprogressive Non-Small-Cell Lung Cancer 163
Epidemiology of prostate cancer and treatment remarks. 162
Stereotactic body radiation therapy salvage reirradiation of radiorecurrent prostatic carcinoma relapsed in the prostatic bed 162
Re-irradiation with curative intent in patients with squamous cell carcinoma of the head and neck: a national survey of usual practice on behalf of the Italian Association of Radiation Oncology (AIRO) 162
1539 poster TUMOR CONTROL PROBABILITY IN STEREOTACTIC RADIO-SURGERY FOR BRAIN METASTASES 162
Hypofractionated high-dose radiation therapy for prostate cancer: long-term results of a multi-institutional phase II trial. 162
Retrospective comparison of external beam radiotherapy and radical prostatectomy in high-risk, clinically localized prostate cancer 158
EORTC radiation proctitis-specific quality of life module - pretesting in four European countries 158
Is stereotactic body radiation therapy an attractive option for unresectable liver metastases? A preliminary report from a phase 2 trial 157
A prospective phase III randomized trial of hypofractionation versus conventional fractionation in patients with high-risk prostate cancer 156
A multicenter LArge retrospectIve daTabase on the personalization of stereotactic ABlative radiotherapy use in lung metastases from colon-rectal cancer: The LaIT-SABR study 156
Color Doppler quantitative measures to predict outcome of biopsies in prostate cancer 155
Patterns of CT lung injury and toxicity after stereotactic radiotherapy delivered with helical tomotherapy in early stage medically inoperable NSCLC 155
Dose and polymorphic genes xrcc1, xrcc3, gst play a role in the risk of developing erythema in breast cancer patients following single shot partial breast irradiation after conservative surgery 154
Phase II study of a four-week hypofractionated external beam radiotherapy regimen for prostate cancer: report on acute toxicity 154
Updated Results and Pattern of Failure in a Randomized Hypofractionation Trial for High-risk Prostate Cancer 151
Mathematical Model for Evaluating Incidence of Acute Rectal Toxicity During Conventional or Hypofractionated Radiotherapy Courses for Prostate Cancer 150
Retreatment for prostate cancer with stereotactic body radiation therapy (SBRT): Feasible or foolhardy? 149
Clinical and Dosimetric Predictors of Acute Toxicity After a 4-Week Hypofractionated External Beam Radiotherapy Regimen for Prostate Cancer: Results From a Multicentric Prospective Trial 148
Salvage therapy of intraprostatic failure after radical external-beam radiotherapy for prostate cancer: A review. 148
Accelerated hyperfractionated radiotherapy and concurrent protracted venous infusion chemotherapy in locally advanced head and neck cancer 146
Stereotactic ablative radiation therapy in renal cell carcinoma: From oligometastatic to localized disease 146
Phase I-II study of hypofractionated simultaneous integrated boost using volumetric modulated arc therapy for adjuvant radiation therapy in breast cancer patients: a report of feasibility and early toxicity results in the first 50 treatments 145
From chemotherapy to target therapies associated with radiation in the treatment of NSCLC: a durable marriage? 144
Moderately escalated hypofractionated (chemo) radiotherapy delivered with helical intensity-modulated technique in stage III unresectable non-small cell lung cancer 143
Review and uses of stereotactic body radiation therapy for oligometastases 142
Linac based SBRT for prostate cancer in 5 fractions with VMAT and flattening filter free beams: Preliminary report of a phase II study 141
Intensity-modulated pelvic radiation therapy and simultaneous integrated boost to the prostate area in patients with high-risk prostate cancer: a preliminary report of disease control 141
Totale 21.642
Categoria #
all - tutte 90.763
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 90.763


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021234 0 0 0 0 0 0 0 0 0 0 115 119
2021/20221.056 83 133 115 49 27 53 42 178 41 35 88 212
2022/20231.648 275 484 194 75 69 271 30 56 100 15 48 31
2023/20241.502 30 23 34 144 164 358 385 29 169 26 32 108
2024/20258.242 148 583 159 142 278 93 513 192 525 733 2.408 2.468
2025/20269.848 1.184 992 875 1.209 980 503 1.450 587 937 910 221 0
Totale 27.471